Ikena Oncology Inc

NASDAQ:IKNA 1:00:00 PM EDT

2.36

-0.20 (-7.81%)

2:37:51 PM EDT: $2.09 -0.27 (-11.44%)

Market Cap (Intraday)	78.88M
Current PE	N/A
Forward PE	N/A
2yr Forward PE	N/A

See more stats

Estimates Current Quarter

Revenue	$19.96 Million
Adjusted EPS	-$0.15

See more estimates

10-Day MA	$2.30
50-Day MA	$2.94
200-Day MA	$4.76

See more pivots

Ikena Oncology Inc Stock, NASDAQ:IKNA

645 Summer Street, Suite 101, Boston, Massachusetts 02210

United States of America

Phone: +1.857.273.8343

Number of Employees: 67

http://www.ikenaoncology.com

Description

Ikena Oncology, Inc. is a clinical stage biotechnology company. It discovers and develops patient directed, biomarker driven therapies for cancer patients. Its product pipeline includes IK-930, RAS Signaling, IK-175, IK-412 and IK-007. The company was founded by Mark Manfredi and George Georgiou in February 2016 and is headquartered in Boston, MA.